The Clinical Observation with Ruxolitinib as Graft-Versus-Host Disease Prophylaxis for Children with Thalassemia after Unrelated or Haploidentical Allo-Hematopoietic Stem Cell Transplantation.
10.19746/j.cnki.issn.1009-2137.2022.05.044
- Author:
Ya-Mei CHEN
1
;
Xiu-Li HONG
1
;
Jin-Zong LIN
1
;
Jie SHI
1
;
Quan-Yi LU
2
Author Information
1. Department of Hematology，Zhongshan Hospital of Xiamen University, Xiamen 361004, Fujian Province, China.
2. Department of Hematology，Zhongshan Hospital of Xiamen University, Xiamen 361004, Fujian Province, China,E-mail: luquanyi@xmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
allogeneic hematopoietic stem cell transplantation;
children;
graft-versus-host disease;
ruxolitinib;
thalassemia
- MeSH:
Antiviral Agents/therapeutic use*;
Child;
Graft vs Host Disease/prevention & control*;
Hematopoietic Stem Cell Transplantation/adverse effects*;
Humans;
Immunosuppressive Agents/therapeutic use*;
Nitriles;
Pyrazoles;
Pyrimidines;
Retrospective Studies;
Thalassemia
- From:
Journal of Experimental Hematology
2022;30(5):1586-1589
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To retrospectively analyze the efficacy and safety of ruxolitinib therapy for children with thalassemia after unrelated or haploidentical stem cell transplantation.
METHODS:From March 2020 to March 2021, 22 patients received successfully allogeneic hematopoietic stem cell transplantation in the Zhongshan Hospital of Xiamen University, from +30 to 100 days,those patients received ruxolitinib therapy (2.5 mg, twice daily) and all adverse reactions were observed, include aGVHD, cGVHD, CMV and EBV infection.
RESULTS:22 patients underwent allogeneic stem cell transplantation, 5 patients were diagnosed as aGVHD, 3 patients had grade I－II skin GVHD and 2 patients had grade II intestinal GVHD, those patients were cured. All patients were followed up for more than 21 weeks, 4 cases developed cGVHD, including 3 cases of localized liver GVHD and 1 case of pulmonary GVHD, those were relieved after active treatment. 8 patients had elevated EBV copies (>3×103/ml), and 3 patients had increased CMV copies, the patients recovered after immunosuppressant and antiviral treatment. There was no CMV infection and EBV related post-transplantant lymphoproliferative disorders(PTLD), and no transplant related deaths.
CONCLUSION:Ruxolitinib can effectively reduce the incidence and severity of GVHD without affecting the hematopoietic recovery, and improve the survival status of thalassemia children after transplantation.
